Two former Insys Therapeutics salespeople indicted in a kickback scheme pleaded not guilty in Manhattan federal court Wednesday. The two are the latest ex-…

Novartis says it turned up no rule-breaking after investigating of potentially improper payments in Turkey. But an official in Ankara now tells Reuters that…

It’s a great day for Belgium’s UCB pharma, thanks to a U.S. District Court patent ruling. In fact, it’s one of the company's best days in years.

Merck & Co. was sitting pretty earlier this year after winning a legal dispute over sofosbuvir, the active ingredient in Gilead's multibillion-dollar…

A Pfizer deal is at the center of another round of insider trading charges. This time, the buyout is Pfizer’s 2010 King Pharmaceuticals deal, and it’s a lawyer…

Valeant’s management is assuring investors that the company is well on its way to stabilizing. But now, it's facing what could be its most serious…

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up,…